Search Results - "Arpornwirat, W." :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

A phase 1b study of IMU-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

A phase 1b study of IMU-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

by Maglakelidze, M., Yau, T., Bulat, I., Yen, C., Chao, Y., Bai, L., Good, A., Ede, N., Chong, L., Tanasanvimon, S., Charoetum, C., Loong, H., Lausoontornsiri, W., Arpornwirat, W., Maneechavakajon, J., Ungtrakul, T., Chou, W.
Published in Annals of oncology (01.07.2019)

Get full text

Journal Article

Serum p53 antibodies in correlation to other biological parameters of breast cancer

Serum p53 antibodies in correlation to other biological parameters of breast cancer

by Sangrajrang, S, Arpornwirat, W, Cheirsilpa, A, Thisuphakorn, P, Kalalak, A, Sornprom, A, Soussi, T
Published in Cancer detection and prevention (01.01.2003)

Get full text

Journal Article

Safety and efficacy of the novel antiemetic neurokinin-1 (NK-1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC) – subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial

Safety and efficacy of the novel antiemetic neurokinin-1 (NK-1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC) – subgroup analysis from a randomized, double-blind, placebo-controlled phase II trial

by Herrstedt, J, Arpornwirat, W, Albert, I, Hansen, V.L, Bandekar, R.R, Levin, J, Grunberg, S.M
Published in European journal of cancer supplements (2008)

Get full text

Journal Article

A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

A Phase Ib Study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

by Chao, Y., Maglakelidze, M., Bulat, L.V., Yau, T., Tanasanvimon, S., Charoentum, C., Arpornwirat, W., Maneechavakajorn, J., Dechaphunkul, A., Ungtrakul, T., Yen, C.-J., Bai, L.-Y., Chou, W.-C., Weidermann, U., Garner-Spitzer, E., Ede, N., Chong, L., Good, A.
Published in Annals of oncology (01.11.2019)

Get full text

Journal Article

SO-004A phase 1b study of IMU-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

SO-004A phase 1b study of IMU-131 her2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

by Maglakelidze, M, Yau, T, Bulat, I, Yen, C, Chao, Y, Bai, L, Good, A, Ede, N, Chong, L, Tanasanvimon, S, Charoetum, C, Loong, H, Lausoontornsiri, W, Arpornwirat, W, Maneechavakajon, J, Ungtrakul, T, Chou, W
Published in Annals of oncology (01.07.2019)

Get full text

Journal Article

1212P - Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer

1212P - Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer

by Wiedermann, U., Garner-Spitzer, E., Chao, Y., Bulat, I., Dechaphunkul, A., Arpornwirat, W., Charoentum, C., Yen, C.J., Yau, T., Maglakelidzde, M., Tanasanvimon, S., Maneechavakajorn, J., Sookprasert, A., Bai, L.-Y., Chou, W.-C., Ungtrakul, T., Zielinski, C.C., Chong, L., Ede, N., Good, A.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

1212PComprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer

1212PComprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer

by Wiedermann, U, Garner-Spitzer, E, Chao, Y, Bulat, I, Dechaphunkul, A, Arpornwirat, W, Charoentum, C, Yen, C J, Yau, T, Maglakelidzde, M, Tanasanvimon, S, Maneechavakajorn, J, Sookprasert, A, Bai, L-Y, Chou, W-C, Ungtrakul, T, Zielinski, C C, Chong, L, Ede, N, Good, A
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer

Comprehensive results of a phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer

by Wiedermann, U., Garner-Spitzer, E., Chao, Y., Bulat, I., Dechaphunkul, A., Arpornwirat, W., Charoentum, C., Yen, C.J., Yau, T., Maglakelidzde, M., Tanasanvimon, S., Maneechavakajorn, J., Sookprasert, A., Bai, L.-Y., Chou, W.-C., Ungtrakul, T., Zielinski, C.C., Chong, L., Ede, N., Good, A.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

Abstract P4-13-09: Clinical effectiveness of everolimus and exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study

Abstract P4-13-09: Clinical effectiveness of everolimus and exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study

by Im, Y-H, Uslu, R, Lee, KS, Nagarkar, R, Sohn, J, Sevinc, A, Altundag, K, Chang, Y-C, Abdel-Razeq, H, Im, S-A, Jeong, J, Park, HY, Arpornwirat, W, Bastick, P, Le, TH, Ocak Arikan, O, Xue, HL, Canatar, A, Valenti, R, Kim, S-B
Published in Cancer research (Chicago, Ill.) (15.02.2016)

Get full text

Journal Article

Abstract P3-14-24: Overall Survival Benefit Observed with Lapatinib (L) Plus Paclitaxel (P) as First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer (MBC)

Abstract P3-14-24: Overall Survival Benefit Observed with Lapatinib (L) Plus Paclitaxel (P) as First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer (MBC)

by Guan, Z-z, Xu, B-h, Arpornwirat, W, Tong, Z-s, Lorvidhaya, V, Wang, L, Newstat, B, DeSilvio, M, Moore, Y, Shen, Z-Z.
Published in Cancer research (Chicago, Ill.) (15.12.2010)

Get full text

Journal Article

Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC)

Phase III results of a novel oral neurokinin-1 (NK-1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC)

by Grunberg, S. M., Aziz, Z., Shaharyar, A., Herrstedt, J., Roila, F., VanBelle, S., Bandekar, R. R., Guckert, M. E., Russo, M. W., Arpornwirat, W.
Published in Journal of clinical oncology (20.05.2008)

Get full text

Journal Article

Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC)

Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC)

by Aziz, Z., Arpornwirat, W., Herrstedt, J., Camlett, I., Piontek, T., Ranganathan, S., Schnyder, J., Bandekar, R. R., Levin, J., Shaharyar, A.
Published in Journal of clinical oncology (20.05.2008)

Get full text

Journal Article

Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC)

Multicenter, randomized, double-blind, ondansetron (ond)-controlled, dose-ranging, parallel group trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC)

by Arpornwirat, W., Albert, I., Hansen, V. L., Russo, M. A., Ross, G. A., Pence, C. D., Bandekar, R. R., Grunberg, S. M.
Published in Journal of clinical oncology (20.06.2006)

Get full text

Journal Article